IDBiologics

IDBiologics is a private, clinical-stage biotech company based in Memphis, Tennessee, specializing in antibody therapeutics for infectious diseases. The company's core asset is an innovative, fully human monoclonal antibody discovery and optimization platform originating from Vanderbilt University, enabling rapid development of candidates with demonstrated proof-of-concept in animal models. With six clinical lead candidate molecules targeting diverse pathogens and a recent contract from the Department of Defense, IDBiologics is positioned to address significant unmet medical needs in pandemic preparedness and endemic infections. The company operates as a pre-revenue entity advancing a pipeline from pre-clinical and clinical development.

Fully human monoclonal antibody discovery and optimization platform, enabling rapid isolation of broad and potent neutralizing antibodies from human B cells. Derived from the laboratory of Professor James Crowe at Vanderbilt University Medical Center.

The field of infectious disease antibodies is highly competitive, involving large pharmaceutical companies (e.g., Regeneron, AstraZeneca) and numerous biotechs. IDBiologics differentiates through its speed and breadth derived from its academic-validated human antibody platform, but must compete for funding, partnerships, and market share.